The Ahmedabad based pharmaceutical company Troikaa Pharmaceutical Ltd will be investing Rs 100 crore for setting up a new manufacturing facility at Sanad, Ahmedabad. The construction work of the new facility will commence from early 2010.

The new facility will be for injectables, tablets, capsules topical preparations, beta - lectum and some oncology products. At present its 140 products are sold in the domestic and the international markets for pain management, critical care, anaesthesia and cardiology segments. The company has strong product pipeline in these therapeutic areas. It has seven new injectables, six beta lectum and six topicals product in the pipeline and very soon it will be in market.

The company has two manufacturing facilities at Ahmedabad and Dehradun (Uttaranchal). Both the facilities are certified by the World Health Organisation. Troikaa has the capability to manufacture high quality critical care injectables, tablets and topical preparations. It holds patented technology platforms for various novel drug delivery system - Intra oral, oral, parenteral, sustain release and topical.

Speaking to Pharmabiz, Ketan Patel, director, said, "We have acquired 65 acre of land at Ahmedabad and our new facility will be as per the US FDA standards. In the first phase of our expansion, we will be investing Rs 60 crore. The facility will be manufacturing injectables, tropical preparation and beta lectum product for the regulated markets. The new facility will start commercial production activity by the end of 2010. We have planned to appoint nearly 250 staff in our new facility".

The company is constantly striving towards attaining technology breakthrough which is in accordance with its promise of providing better treatment options and drug delivery system. At present it holds two patents and five are in the process. A few months back, it has launched its product Dynapar AQ injection 75/mg/1ml injecton in the domestic market. It offers higher bioavailability compared to conventional 3ml Diclofenac injection. Studies show that majority of intra-gluteal injections may actually be subcutaneous and the rate of absorption is faster when given intradeltoid rather than intra-gluteal. Moreover, smaller volume of concentrated solution cause less muscle damage compared to larger volume of relatively less concentrated solution. Currently, in Mumbai more than 90 per cent hospitals are using it. "As Union Budget has given good incentives to the upcoming hospitals. This may help setting up of many hospitals in the tier II and III cities. We are expecting that our total sales revenue of the Dynapar injection in 2007-08 should touch Rs 25 crore and in the next fiscal it will reach up to 40 crore".

With the growth rate of 40 per cent, its annual turnover during 2006-07 went up to Rs 105 crore and for the current year it will reach to Rs 140 crore. The company is targeting to touch Rs 300 crore in the coming fiscal.